Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Brivanib Clear all
Completed Phase 1Phase 2 Interventional

Phase I/II Combination With Irinotecan- Erbitux

NCT00594984
View directory record Official record
Conditions
Metastatic Colorectal Cancer (MCRC)
Interventions
Cetuximab, Irinotecan, Brivanib, Brivanib Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Louisville, Kentucky • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 3, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional Results available

Brivanib Metastatic Renal Cell Carcinoma

NCT01253668
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Brivanib alaninate, Polymerase chain reaction, Iodine I 124 chimeric monoclonal antibody G250, Positron emission tomography/computed tomography, Protein expression analysis, Immunohistochemistry
Drug · Genetic · Other + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

NCT00207103
View directory record Official record
Conditions
Tumors, Neoplasm Metastasis
Interventions
Brivanib, Brivanab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
3
States / cities
Santa Monica, California • Indianapolis, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 3, 2008 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT01267253
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Persistent Disease, Recurrent Cervical Carcinoma
Interventions
Brivanib Alaninate, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Burbank, California • San Francisco, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 3 Interventional

First Line Hepato Cellular Carcinoma (HCC)

NCT00858871
View directory record Official record
Conditions
Hepato Cellular Carcinoma (HCC)
Interventions
Brivanib, Placebo, Sorafenib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Downey, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 3 Interventional

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

NCT00908752
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Brivanib, Brivanib Placebo, TACE Therapy
Drug · Other · Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2019 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

NCT00437424
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Brivanib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Clleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

NCT00798252
View directory record Official record
Conditions
Advanced Cancer
Interventions
Capecitabine, Doxorubicin, Ixabepilone, Docetaxel, Paclitaxel, Brivanib alaninate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 6, 2015 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00888173
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma
Interventions
Brivanib Alaninate, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
35
States / cities
Aurora, Colorado • New Britain, Connecticut • Chicago, Illinois + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

NCT00355238
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
brivanib (active)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

NCT01046864
View directory record Official record
Conditions
Gastro-Intestinal Cancer
Interventions
5-FU, Leucovorin, Irinotecan, Brivanib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
20 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Dallas, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

NCT00207051
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Brivanib + Cetuximab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 3 Interventional

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

NCT00825955
View directory record Official record
Conditions
Liver Cancer
Interventions
Brivanib, Placebo, Best Supportive Care
Drug · Other · Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
19
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 3, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional Results available

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

NCT01367275
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Adenocarcinoma
Interventions
Brivanib, Irinotecan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

NCT00435669
View directory record Official record
Conditions
Tumors
Interventions
Brivanib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Sep 3, 2026, 11:02 AM EDT
Terminated Phase 1 Interventional

Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies

NCT00300027
View directory record Official record
Conditions
Gastrointestinal Neoplasms
Interventions
BMS-582664
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 2 Interventional

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

NCT00633789
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma, Soft Tissue Sarcoma, Gastric/Esophageal Adenocarcinoma, Pancreatic Cancer Including Ampulla of Vater
Interventions
brivanib, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
6
States / cities
Chicago, Illinois • Evanston, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)

NCT00437437
View directory record Official record
Conditions
Tumors
Interventions
Brivanib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Detroit, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 3, 2026, 11:02 AM EDT